WO2002064172A3 - Fhit gene therapy prevents tumor development in fhit-deficient mice - Google Patents
Fhit gene therapy prevents tumor development in fhit-deficient mice Download PDFInfo
- Publication number
- WO2002064172A3 WO2002064172A3 PCT/US2002/004155 US0204155W WO02064172A3 WO 2002064172 A3 WO2002064172 A3 WO 2002064172A3 US 0204155 W US0204155 W US 0204155W WO 02064172 A3 WO02064172 A3 WO 02064172A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fhit
- gene therapy
- tumor development
- deficient mice
- prevents tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01029—Bis(5'-adenosyl)-triphosphatase (3.6.1.29)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26809001P | 2001-02-12 | 2001-02-12 | |
US60/268,090 | 2001-02-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002064172A2 WO2002064172A2 (en) | 2002-08-22 |
WO2002064172A3 true WO2002064172A3 (en) | 2003-02-27 |
Family
ID=23021427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/004155 WO2002064172A2 (en) | 2001-02-12 | 2002-02-12 | Fhit gene therapy prevents tumor development in fhit-deficient mice |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2002064172A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8911998B2 (en) | 2007-10-26 | 2014-12-16 | The Ohio State University | Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof |
US9125923B2 (en) | 2008-06-11 | 2015-09-08 | The Ohio State University | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2719773A3 (en) | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
CN103866008B (en) | 2007-08-03 | 2016-06-29 | 俄亥俄州立大学研究基金会 | The super conservative region of coding NCRNA |
CN102803511A (en) | 2009-11-23 | 2012-11-28 | 俄亥俄州立大学 | Materials and methods useful for affecting tumor cell growth, migration and invasion |
AU2011326032B2 (en) | 2010-11-12 | 2016-10-06 | The Ohio State University Research Foundation | Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer |
BR112013011942A2 (en) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulation, drug dosage form for oral transmucosal administration, transmucosal drug delivery system, method of treatment and prophylaxis of a disease or disorder, method of treatment, formulation, method for treatment or prevention of head and neck squamous cell carcinoma (hnscc), method for chemoprevention of an oral cancer or precancerous condition, method for increasing the concentration of a retinide composition, method of treatment and prophylaxis of a disease or condition, ratification method of a subject presenting a symptomatic medical condition , method of treating an oral cancer or precancerous condition in a patient, method for making an oral drug delivery system, method for increasing the release and permeation of a retinide composition. |
JP2014509852A (en) | 2011-03-07 | 2014-04-24 | ジ・オハイオ・ステート・ユニバーシティ | Mutagenic activity induced by microRNA-155 (miR-155) links inflammation and cancer |
AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
CN104619353A (en) | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis |
AU2013209477B2 (en) | 2012-01-20 | 2016-12-08 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
CN108715860A (en) * | 2018-04-20 | 2018-10-30 | 郑州大学 | A kind of construction method of epithelium of esophagus tissue p53 specific knockdowns mouse esophageal precancerous lesion model |
EP4205799B1 (en) | 2021-12-29 | 2024-02-14 | Cairdac | Implantable medical device with non-traumatic helical anchoring screw |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029119A1 (en) * | 1996-02-09 | 1997-08-14 | Thomas Jefferson University | Fhit proteins and nucleic acids and methods based thereon |
-
2002
- 2002-02-12 WO PCT/US2002/004155 patent/WO2002064172A2/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029119A1 (en) * | 1996-02-09 | 1997-08-14 | Thomas Jefferson University | Fhit proteins and nucleic acids and methods based thereon |
Non-Patent Citations (7)
Title |
---|
CROCE CARLO M ET AL: "Role of FHIT in human cancer.", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 5, May 1999 (1999-05-01), pages 1618 - 1624, XP001095626, ISSN: 0732-183X * |
DUMON KRISTOFFEL R ET AL: "FHIT gene therapy prevents tumor development in Fhit-deficient mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 6, 13 March 2001 (2001-03-13), March 13, 2001, pages 3346 - 3351, XP002209368, ISSN: 0027-8424 * |
DUMON KRISTOFFEL R ET AL: "Inhibition of tumor growth and induction of apoptosis by adeno associated virus mediated fragile histidine triade (FHIT) gene overexpression in pancreatic cancer cell lines.", GASTROENTEROLOGY, vol. 118, no. 4 Suppl. 2 Part 1, April 2000 (2000-04-01), 101st Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week.;San Diego, California, USA; May 21-24, 2000, pages AGA A643, XP001095640, ISSN: 0016-5085 * |
FONG LOUISE Y Y ET AL: "Muir-Torre-like syndrome in Fhit-deficient mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 9, 25 April 2000 (2000-04-25), pages 4742 - 4747, XP002204095, ISSN: 0027-8424 * |
ISHII HIDESHI ET AL: "Potential cancer therapy with the fragile histidine triad gene: Review of the preclinical studies.", JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), vol. 286, no. 19, 21 November 2001 (2001-11-21), pages 2441 - 2449, XP001098544, ISSN: 0098-7484 * |
JI LIN ET AL: "Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 14, 15 July 1999 (1999-07-15), pages 3333 - 3339, XP002204093, ISSN: 0008-5472 * |
ROZ L ET AL: "Adenoviral transfer of the FHIT gene in cancer cell lines results in apoptosis and activation of the caspase-8 pathway", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, no. 4 Supplement 2, October 2000 (2000-10-01), pages 102, XP002204092, ISSN: 0002-9297 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8911998B2 (en) | 2007-10-26 | 2014-12-16 | The Ohio State University | Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof |
US9125923B2 (en) | 2008-06-11 | 2015-09-08 | The Ohio State University | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy |
Also Published As
Publication number | Publication date |
---|---|
WO2002064172A2 (en) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE50002293D1 (en) | USE OF CSF-1 INHIBITORS | |
WO2002064172A3 (en) | Fhit gene therapy prevents tumor development in fhit-deficient mice | |
WO1999046279A3 (en) | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | |
HUP0200093A2 (en) | Trpm-2 antisense therapy | |
ATE380548T1 (en) | USE OF P53 INHIBITORS FOR THE TREATMENT OF ADVERSE SYMPTOMS OF CANCER THERAPY | |
AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
DK1228208T3 (en) | 36P6D5: secreted tumor antigen | |
ATE319447T1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING CLAVULANIC ACID OR DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
AU1656501A (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
AU2002314901A1 (en) | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer | |
NZ285159A (en) | Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene | |
AU2001249549A1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
DE69426334T2 (en) | Parenteral busulfan for the treatment of malignant diseases | |
GB2405147A (en) | Therapeutic molecules and methods-1 | |
WO2002066044A3 (en) | Method for dendritic cells based immunotherapy of tumors using combination therapy | |
HK1068261A1 (en) | Combinations comprisinga selective cyclooxygenase-2 inhibitor | |
PT1390371E (en) | OXAZOLO- AND FUROPYRIMIDINES AND THEIR USE IN MEDICINES AGAINST TUMORS | |
WO2000040229A3 (en) | Synergistic tumorcidal response induced by histamine | |
WO2002087503A3 (en) | Compositions and methods for treating colorectal polyps and cancer | |
WO2005048944A3 (en) | Activatable photodynamic therapy agents | |
AU2002251754A1 (en) | Therapeutic modulation of the tumor inflammatory response | |
AU3282300A (en) | Molecules for the treatment and diagnosis of tumors | |
WO2000004153A3 (en) | Repression of cell transformation with human pea3 | |
WO2002008456A3 (en) | Method for identifying metastatic tumor cells | |
EP1321146A3 (en) | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |